MAYNF Stock Chart & Stats
$2.30
-$0.18(-8.65%)
At close: 4:00 PM EDT
$2.30
-$0.18(-8.65%)
Day’s Range― - ―
52-Week Range$1.40 - $4.25
Previous CloseN/A
Volume5.30K
Average Volume (3M)1.51K
Market Cap
$184.54M
Enterprise Value$224.67
Total Cash (Recent Filing)$82.25M
Total Debt (Recent Filing)$43.20M
Price to Earnings (P/E)10.2
Beta0.89
Next Earnings
Feb 24, 2027EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend Yield255.26%
Share Statistics
EPS (TTM)0.31
Shares Outstanding81,890,884
10 Day Avg. Volume600
30 Day Avg. Volume1,510
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.57
Price to Sales (P/S)0.58
P/FCF Ratio17.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.70Price Target Upside17.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$272.75M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a substantial equity base provide financial flexibility to fund product launches, manufacturing investment and disciplined expansion. This reduces balance-sheet risk while the company works to restore more consistent operating profitability.
Women's Health GrowthGrowth across key women's-health products, together with 15 million additional covered lives, supports a durable commercial platform. Broader coverage and menopause-market expansion could improve prescription volumes and margins over the next several quarters.
DistributeRx ExpansionThe platform expands Mayne's route to market beyond traditional channels and includes 208 third-party products alongside its own portfolio. Prescriber adoption, partner conversion and sevenfold planned capacity growth could create a scalable distribution-led revenue stream.
Bears Say
Revenue And EBITDA PressureThe simultaneous decline in revenue and underlying EBITDA indicates that commercial growth has not yet offset pricing, investment and cost pressures. Persistently weaker earnings would constrain reinvestment and make margin recovery dependent on successful execution.
Weak Core Operating ProfitabilityPositive net income has not yet translated into sustainable operating profitability, suggesting that charges, costs or other items continue to weigh on the core business. A negative EBIT margin leaves limited room for execution setbacks or competitive pricing pressure.
Dermatology CompetitionCoverage losses and generic entry can reduce prescription access, pricing power and product contribution in dermatology. These pressures may persist beyond a single quarter as payers and competitors reshape the market, challenging the sustainability of recent margin gains.
Mayne Pharma Group News
MAYNF FAQ
What was Mayne Pharma Group’s price range in the past 12 months?
Mayne Pharma Group lowest stock price was $1.40 and its highest was $4.25 in the past 12 months.
What is Mayne Pharma Group’s market cap?
Mayne Pharma Group’s market cap is $184.54M.
When is Mayne Pharma Group’s upcoming earnings report date?
Mayne Pharma Group’s upcoming earnings report date is Feb 24, 2027 which is in 167 days.
How were Mayne Pharma Group’s earnings last quarter?
Mayne Pharma Group released its earnings results on Aug 26, 2026. The company reported -$0.261 earnings per share for the quarter, missing the consensus estimate of -$0.245 by -$0.016.
Is Mayne Pharma Group overvalued?
According to Wall Street analysts Mayne Pharma Group’s price is currently Undervalued.
Does Mayne Pharma Group pay dividends?
Mayne Pharma Group pays a Notavailable dividend of $0.378 which represents an annual dividend yield of 255.26%. See more information on Mayne Pharma Group dividends here
What is Mayne Pharma Group’s EPS estimate?
Mayne Pharma Group’s EPS estimate is -0.12.
How many shares outstanding does Mayne Pharma Group have?
Mayne Pharma Group has 81,890,884 shares outstanding.
What happened to Mayne Pharma Group’s price movement after its last earnings report?
Mayne Pharma Group reported an EPS of -$0.261 in its last earnings report, missing expectations of -$0.245. Following the earnings report the stock price went down -1.957%.
Which hedge fund is a major shareholder of Mayne Pharma Group?
Currently, no hedge funds are holding shares in MAYNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mayne Pharma Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.70 (17.42% Upside)
$2.70 (17.42% Upside)
Blogger Sentiment
Bullish
MAYNF Sentiment 83%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-37.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mayne Pharma Group
Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia. The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products. Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients. Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases. Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.
MAYNF Company Deck
MAYNF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: clear operational progress (notably gross margin expansion, successful DistributeRx launch and dermatology margin improvement) and meaningful product‑level growth in women's health (NEXTSTELLIS, BIJUVA, IMVEXXY). However, these positives were offset by weaker headline revenue (‑6%), a 27% decline in underlying EBITDA, significant one‑off and litigation‑related costs, an $11M impact from ANNOVERA returns, and a decline in international contribution (‑38%). Management highlighted a path to margin improvement and capacity expansion that support future upside, but near‑term financial pressures and legal distractions temper the outlook.View all MAYNF earnings summariesMAYNF Stock 12 Month Forecast
Average Price Target
$2.70
▲(17.42% Upside)
Technical Analysis
Starpharma Holdings Limited
―
Vita Life Sciences Limited
―
Medical Developments International Limited
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Ownership Overview
0.31% Insiders
3.55% Mutual Funds
<0.01% Other Institutional Investors
94.17% Public Companies and
Individual Investors